A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non–Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non–Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)

Published:2021-10 Issue: Volume: Page:
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Shiraishi Yoshimasa,Hakozaki Taiki^ORCID,Nomura Shogo^ORCID,Kataoka Tomoko,Tanaka Kentaro^ORCID,Miura Satoru^ORCID,Sekino Yuta^ORCID,Ando Masahiko,Horinouchi Hidehito^ORCID,Ohe Yuichiro,Okamoto Isamu

Funder

Eli Lilly and Company

Astellas Pharma

National Cancer Center

Pfizer

Japan Agency for Medical Research and Development

AstraZeneca

Taiho Pharmaceutical

Novartis

Chugai Pharmaceutical

Bristol-Myers Squibb

Kyowa Hakko Kirin

Meso Scale Diagnostics

Boehringer Ingelheim

Amgen

AbbVie

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference11 articles.

1. Global cancer statistics, 2012;Torre;CA: a cancer j for clinicians,2015

2. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis;Lee;J National Cancer Institute,2013

3. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;The New England j med,2018

4. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;The New England j med,2018

5. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial;West;The Lancet. Oncology.,2019

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bibliometric analysis of bone metastases from lung cancer research from 2004 to 2023;Frontiers in Oncology;2024-08-06

2. The role of the gut microbiota in tumor, immunity, and immunotherapy;Frontiers in Immunology;2024-06-05

3. Risk factors for severe immune‐related pneumonitis after nivolumab plus ipilimumab therapy for non‐small cell lung cancer;Thoracic Cancer;2024-06-03

4. Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis;Journal of Cancer Research and Clinical Oncology;2024-04-26

5. Long‐term survival with systemic therapy in the last decade: Can melanoma be cured?;The Journal of Dermatology;2024-02-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3